HUMIRA approved for non-infectious panuveitis treatment

Published: 2016-12-19 13:48:32

Updated: 2016-12-19 13:48:32

On the 15^th, Abbvie Korea(CEO Hong-Ki Yoo) and Eisai Korea(CEO Hong-Byung Ko) announced they acquired the Korean Ministry of Food and Drug Safety’s approval for the non-infectious intermediate, posterior and panuveitis treatment for adults who have had an inadequate response to corticosteroid.

Humira, the first and only biomedicine approved as a non-infectious panuveitis treatment in Korea, ac...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.